Long-term complications in Hodgkin's lymphoma survivors. 2012

Saadettin Kilickap, and Ibrahim Barista, and Sukran Ulger, and Ismail Celik, and Ugur Selek, and Ibrahim Güllü, and Ferah Yildiz, and Ayse Kars, and Yavuz Ozisik, and Gülten Tekuzman
Department of Medical Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey. skilickap@yahoo.com

Background. Although patients with Hodgkin's lymphoma (HL) achieve prolonged survival, long-term complications are a major cause of morbidity and mortality among long-term survivors of HL. Methods. We retrospectively evaluated long-term complications in 336 HL survivors treated between January 1990 and January 2006 at the Department of Medical Oncology of the Hacettepe University Institute of Oncology who were >16 years old at presentation. All patients were regularly followed up every 3 months for the first 2 years after complete response, biannually for 3 years, and annually after 5 years. Results. Median follow-up was 8.5 years. The mean age (±SD) of the patients at the time of diagnosis was 35.7 ± 13.1 years. The male to female ratio was 61%/39%. During follow-up, 29 second malignancies (8.6%) were diagnosed in 28 patients with HL; 22 were solid tumors and 7 were hematological malignancies. Forty-seven (14.0%) of all patients with HL were found to have thyroid abnormalities. During follow-up, 54 (16.1%) patients developed cardiovascular complications. Overall, 29 (8.6%) patients developed late pulmonary toxicities. The cumulative number of chronic viral infections was 13 (3.9%). Conclusions. Long-term survivors of HL need to be properly followed up not only for disease control but also for evaluation of possible late morbidities to minimize the consequences.

UI MeSH Term Description Entries
D007037 Hypothyroidism A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction. Central Hypothyroidism,Primary Hypothyroidism,Secondary Hypothyroidism,TSH Deficiency,Thyroid-Stimulating Hormone Deficiency,Central Hypothyroidisms,Deficiency, TSH,Deficiency, Thyroid-Stimulating Hormone,Hormone Deficiency, Thyroid-Stimulating,Hypothyroidism, Central,Hypothyroidism, Primary,Hypothyroidism, Secondary,Hypothyroidisms,Primary Hypothyroidisms,Secondary Hypothyroidisms,TSH Deficiencies,Thyroid Stimulating Hormone Deficiency,Thyroid-Stimulating Hormone Deficiencies
D008171 Lung Diseases Pathological processes involving any part of the LUNG. Pulmonary Diseases,Disease, Pulmonary,Diseases, Pulmonary,Pulmonary Disease,Disease, Lung,Diseases, Lung,Lung Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012137 Respiratory System The tubular and cavernous organs and structures, by means of which pulmonary ventilation and gas exchange between ambient air and the blood are brought about. Respiratory Tract,Respiratory Systems,Respiratory Tracts,System, Respiratory,Tract, Respiratory
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D002319 Cardiovascular System The HEART and the BLOOD VESSELS by which BLOOD is pumped and circulated through the body. Circulatory System,Cardiovascular Systems,Circulatory Systems
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females

Related Publications

Saadettin Kilickap, and Ibrahim Barista, and Sukran Ulger, and Ismail Celik, and Ugur Selek, and Ibrahim Güllü, and Ferah Yildiz, and Ayse Kars, and Yavuz Ozisik, and Gülten Tekuzman
June 2008, International journal of radiation oncology, biology, physics,
Saadettin Kilickap, and Ibrahim Barista, and Sukran Ulger, and Ismail Celik, and Ugur Selek, and Ibrahim Güllü, and Ferah Yildiz, and Ayse Kars, and Yavuz Ozisik, and Gülten Tekuzman
November 2010, Psycho-oncology,
Saadettin Kilickap, and Ibrahim Barista, and Sukran Ulger, and Ismail Celik, and Ugur Selek, and Ibrahim Güllü, and Ferah Yildiz, and Ayse Kars, and Yavuz Ozisik, and Gülten Tekuzman
January 2000, Annals of oncology : official journal of the European Society for Medical Oncology,
Saadettin Kilickap, and Ibrahim Barista, and Sukran Ulger, and Ismail Celik, and Ugur Selek, and Ibrahim Güllü, and Ferah Yildiz, and Ayse Kars, and Yavuz Ozisik, and Gülten Tekuzman
December 1993, Journal of the National Cancer Institute,
Saadettin Kilickap, and Ibrahim Barista, and Sukran Ulger, and Ismail Celik, and Ugur Selek, and Ibrahim Güllü, and Ferah Yildiz, and Ayse Kars, and Yavuz Ozisik, and Gülten Tekuzman
August 1978, Cancer,
Saadettin Kilickap, and Ibrahim Barista, and Sukran Ulger, and Ismail Celik, and Ugur Selek, and Ibrahim Güllü, and Ferah Yildiz, and Ayse Kars, and Yavuz Ozisik, and Gülten Tekuzman
April 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Saadettin Kilickap, and Ibrahim Barista, and Sukran Ulger, and Ismail Celik, and Ugur Selek, and Ibrahim Güllü, and Ferah Yildiz, and Ayse Kars, and Yavuz Ozisik, and Gülten Tekuzman
April 1988, Mayo Clinic proceedings,
Saadettin Kilickap, and Ibrahim Barista, and Sukran Ulger, and Ismail Celik, and Ugur Selek, and Ibrahim Güllü, and Ferah Yildiz, and Ayse Kars, and Yavuz Ozisik, and Gülten Tekuzman
August 2019, Annals of hematology,
Saadettin Kilickap, and Ibrahim Barista, and Sukran Ulger, and Ismail Celik, and Ugur Selek, and Ibrahim Güllü, and Ferah Yildiz, and Ayse Kars, and Yavuz Ozisik, and Gülten Tekuzman
December 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Saadettin Kilickap, and Ibrahim Barista, and Sukran Ulger, and Ismail Celik, and Ugur Selek, and Ibrahim Güllü, and Ferah Yildiz, and Ayse Kars, and Yavuz Ozisik, and Gülten Tekuzman
January 2023, Acta oncologica (Stockholm, Sweden),
Copied contents to your clipboard!